- Home
- ICCM vs AVTE Comparison
ICCM vs AVTE Comparison
Compare ICCM & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- AVTE
- Stock Information
- Founded
- ICCM 2006
- AVTE 2018
- Country
- ICCM Israel
- AVTE United States
- Employees
- ICCM N/A
- AVTE N/A
- Industry
- ICCM
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- AVTE Health Care
- Exchange
- ICCM Nasdaq
- AVTE Nasdaq
- Market Cap
- ICCM 75.8M
- AVTE 68.7M
- IPO Year
- ICCM N/A
- AVTE 2021
- Fundamental
- Price
- ICCM $1.41
- AVTE $2.37
- Analyst Decision
- ICCM Strong Buy
- AVTE Hold
- Analyst Count
- ICCM 2
- AVTE 7
- Target Price
- ICCM $2.70
- AVTE $11.75
- AVG Volume (30 Days)
- ICCM 379.2K
- AVTE 140.8K
- Earning Date
- ICCM 04-02-2025
- AVTE 03-24-2025
- Dividend Yield
- ICCM N/A
- AVTE N/A
- EPS Growth
- ICCM N/A
- AVTE N/A
- EPS
- ICCM N/A
- AVTE N/A
- Revenue
- ICCM $3,671,000.00
- AVTE N/A
- Revenue This Year
- ICCM $10.03
- AVTE N/A
- Revenue Next Year
- ICCM $62.68
- AVTE N/A
- P/E Ratio
- ICCM N/A
- AVTE N/A
- Revenue Growth
- ICCM 26.02
- AVTE N/A
- 52 Week Low
- ICCM $0.48
- AVTE $1.25
- 52 Week High
- ICCM $1.66
- AVTE $32.42
- Technical
- Relative Strength Index (RSI)
- ICCM 60.09
- AVTE 37.24
- Support Level
- ICCM $1.22
- AVTE $2.35
- Resistance Level
- ICCM $1.66
- AVTE $2.49
- Average True Range (ATR)
- ICCM 0.09
- AVTE 0.10
- MACD
- ICCM 0.01
- AVTE -0.01
- Stochastic Oscillator
- ICCM 43.18
- AVTE 11.43
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.